Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
Impact of androgen deprivation therapy on cardiovascular disease and diabetes
Journal of Clinical Oncology, 06/12/09
Alibhai SMH et al. - In a study to clarify whether androgen deprivation therapy (ADT) is associated with an increased risk of both acute myocardial infarction (AMI) and cardiovascular mortality, it was shown that continuous ADT use for at least 6 mos in older men is associated with increased risk of diabetes and fragility fracture but not AMI or sudden cardiac death.
Methods- Using linked administrative databases, men age 66 yrs or older with prostate cancer (PC) given continuous ADT for at least 6 mos or who underwent bilateral orchiectomy (n = 19,079) were matched with men with PC who had never received ADT.
- Treated and untreated groups were matched 1:1 (ie, hard-matched) on age, prior cancer treatment, and yr of diagnosis and propensity-matched on comorbidities, medications, cardiovascular risk factors, prior fractures, and socioeconomic variables.
- Primary outcomes were development of AMI, sudden cardiac death, and diabetes; fragility fracture was also examined.
- The cohort was observed for a mean of 6.47 yrs.
- In time-to-event analyses, ADT use was associated with an increased risk of diabetes and fragility fracture but not with AMI or sudden cardiac death.
- Increasing duration of ADT was associated with excess risk of fragility fractures and diabetes but not cardiac outcomes.
Today in Renal/Urologic...keeping you current
Receive free subspecialty "5-minute updates" via email
Upfront, randomized, phase II trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma
Cancer, 11/03/09
Risk of dying from prostate cancer in men randomized to screening
Cancer, 10/13/09
Survivin as a prognostic marker for urothelial carcinoma of the bladder: A multicenter external validation study
Clinical Cancer Research, 11/17/09
Today in Side Effects...keeping you current
Receive free subspecialty "5-minute updates" via email
Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes
Journal of Clinical Oncology, 11/12/09
Casopitant improves the quality of life in patients receiving highly emetogenic chemotherapy
Supportive Care in Cancer, 11/06/09
Incidence and Correlates of Radiation Dermatitis in Children and Adolescents Receiving Radiation Therapy for the Treatment of Paediatric Sarcomas
Clinical Oncology, 11/12/09
Sponsor
Article Search
Sponsor
Sponsor


See Latest Articles


